Home・Elenco Azioni・Vericel Corp

Vericel Corp

Chiusa

SettoreSettore sanitario

46.28 1.25

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

45.71

Massimo

47.15

Metriche Chiave
By Trading Economics
Entrata	-30M -6.3M
Vendite	-24M 68M
P/E Media del settore	105.395 64.641
EPS	-0.12
Margine di Profitto	-9.21
Dipendenti	398
EBITDA	-30M -2.9M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+33.81% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	456M 2.3B
Apertura precedente	45.03
Chiusura precedente	46.28

Notizie sul Sentiment di mercato

By Acuity

100%

320 / 340 Classifica in Healthcare

Vericel Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 20:03 UTC

Correlated Moves

Vericel Corp shares are advancing, supported by significant gains in the broader market and major tech stocks, contributing to positive investor sentiment.

31 lug 2026, 20:02 UTC

Correlated Moves

Vericel Corp's price is lower today, influenced by declines in the Biotechnology sub-sector and a falling Russell 2000 Index.

30 lug 2026, 20:36 UTC

Correlated Moves

Vericel Corp shares gained in after-market trading, aligning with a rising Russell 2000 Index. The stock remains above its 20-day moving average.

29 lug 2026, 19:27 UTC

Correlated Moves

Vericel Corp shares declined during Wednesday's session, continuing a downward trend since Tuesday's close, amid broader market weakness reflected in the Russell 2000 Index.

28 lug 2026, 21:02 UTC

Vericel Corp shares are lower in after-market trading, reflecting broader market caution amid declines in the Nikkei 225 Index and technology sector concerns.

27 lug 2026, 20:31 UTC

Vericel Corp shares declined during after-market hours amid unusual selling pressure. The stock remains below its 20-day moving average with no specific news identified.

24 lug 2026, 19:46 UTC

Correlated Moves

Vericel Corp reported first-quarter revenue of $39.2 million, missing estimates. Shares are lower amid broader market declines affecting small-cap biotechnology stocks.

22 lug 2026, 20:13 UTC

Vericel Corp shares are trading higher in after-market hours, influenced by broader market volatility amid rising crude oil prices and geopolitical tensions.

21 lug 2026, 14:31 UTC

Vericel Corp shares are higher, supported by overall market momentum and a recovery in Asian markets, particularly the Nikkei 225 Index.

20 lug 2026, 17:46 UTC

Correlated Moves

Vericel Corp shares are lower today, aligning with a decline in the ARK Genomic Revolution ETF and the Russell 2000 Index.

Confronto tra pari

Modifica del prezzo

Vericel Corp Previsione

Obiettivo di Prezzo

By TipRanks

33.81% in crescita

Previsioni per 12 mesi

Media 61.5 USD 33.81%

Alto 72 USD

Basso 58 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Vericel Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Vericel Corp - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Vericel Corp

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.